Mehmet Salih Aydın , Mehmet Ali Eren , Nida Uyar , Nazım Kankılıç , Hüseyin Karaaslan , Tevfik Sabuncu , Hakim Çelik
{"title":"糖尿病足溃疡患者全身免疫炎症指数与截肢之间的关系。","authors":"Mehmet Salih Aydın , Mehmet Ali Eren , Nida Uyar , Nazım Kankılıç , Hüseyin Karaaslan , Tevfik Sabuncu , Hakim Çelik","doi":"10.1016/j.jos.2023.07.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p><span>The systemic immune inflammation index (SII) is a cost-effective biomarker calculated by lymphocyte, neutrophil and platelet counts and is currently being studied in various diseases. Since there is no study examining the relationship between SII and </span>diabetic foot ulcers (DFU) in the literature, our aim was to investigate the relationship between SII and amputation rate in DFU.</p></div><div><h3>Methods</h3><p>Type 2 DM 511 patients with DFU were screened from 2017 to 2021. Laboratory data obtained on the first day of hospitalization were considered. Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and SII were calculated from routine blood count. Participants were divided into two groups as amputation (Group 1) and non-amputation (Group 2).</p></div><div><h3>Results</h3><p>Amputation rate was 18.8%. The A1c (8.80 (3.26) % vs. 9.52 (3.10) %, p = 0.007) and HGB (10.17 ± 2.16 g/dL vs. 12.05 ± 2.20 g/dL, p < 0.001) levels, and lymphocyte count (1.81 (1.16) vs. 2.05 (1.11), p = 0.015) were significantly lower in Group 1 than Group 2. The counts of WBC (14.01 (9.16) × 10<sup>9</sup>/L vs. 10.41 (5.82) × 10<sup>9</sup>/L), PLT (393.35 (196.98) × 10<sup>9</sup>/L vs. 312.05 (141.33) × 10<sup>9</sup>/L), neutrophil (11.52 (8.75) × 10<sup>9</sup>/L vs. 6.93 (5.96) × 10<sup>9</sup>/L), PLR (226.04 (159.24) × 10<sup>9</sup>/L vs. 153.12 (101.91) × 10<sup>9</sup>/L), NLR (6.64 (6.93) vs. 3.34 (3.99)) and SII (2505.86 (3957.47) × 10<sup>9</sup>/L vs. 1092.50 (1476.08) × 10<sup>9</sup><span>/L), and the levels of CRP (14.12 (12.66) mg/dL vs. 3.86 (12.63) mg/dL) and ESR (87.50 (50.50) mm/h vs. 63.00 (57.25) mm/h) were significantly higher in Group 1 than Group 2 (all p < 0.001). AUC of ROC analysis of PLR was 0.666 (95% CI, 0.604–0.728), NLR was 0.695 (95% CI, 0.638–0.752) and SII was 0.716 (95% CI, 0.661–0.772) for the predicting of amputation and the SII had the best AUC with 67.4% sensitivity and 63.3%specificty.</span></p></div><div><h3>Conclusion</h3><p>SII is a cost-effective and readily available marker, but alone may not be sufficient to predict the risk of amputation in DFU. In our results, the predictive role of SII alone or with other markers for future DFU and its role in predicting other chronic diabetic complications will be evaluated in extensive studies.</p></div>","PeriodicalId":16939,"journal":{"name":"Journal of Orthopaedic Science","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship between systemic immune inflammation index and amputation in patients with diabetic foot ulcer\",\"authors\":\"Mehmet Salih Aydın , Mehmet Ali Eren , Nida Uyar , Nazım Kankılıç , Hüseyin Karaaslan , Tevfik Sabuncu , Hakim Çelik\",\"doi\":\"10.1016/j.jos.2023.07.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim</h3><p><span>The systemic immune inflammation index (SII) is a cost-effective biomarker calculated by lymphocyte, neutrophil and platelet counts and is currently being studied in various diseases. Since there is no study examining the relationship between SII and </span>diabetic foot ulcers (DFU) in the literature, our aim was to investigate the relationship between SII and amputation rate in DFU.</p></div><div><h3>Methods</h3><p>Type 2 DM 511 patients with DFU were screened from 2017 to 2021. Laboratory data obtained on the first day of hospitalization were considered. Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and SII were calculated from routine blood count. Participants were divided into two groups as amputation (Group 1) and non-amputation (Group 2).</p></div><div><h3>Results</h3><p>Amputation rate was 18.8%. The A1c (8.80 (3.26) % vs. 9.52 (3.10) %, p = 0.007) and HGB (10.17 ± 2.16 g/dL vs. 12.05 ± 2.20 g/dL, p < 0.001) levels, and lymphocyte count (1.81 (1.16) vs. 2.05 (1.11), p = 0.015) were significantly lower in Group 1 than Group 2. The counts of WBC (14.01 (9.16) × 10<sup>9</sup>/L vs. 10.41 (5.82) × 10<sup>9</sup>/L), PLT (393.35 (196.98) × 10<sup>9</sup>/L vs. 312.05 (141.33) × 10<sup>9</sup>/L), neutrophil (11.52 (8.75) × 10<sup>9</sup>/L vs. 6.93 (5.96) × 10<sup>9</sup>/L), PLR (226.04 (159.24) × 10<sup>9</sup>/L vs. 153.12 (101.91) × 10<sup>9</sup>/L), NLR (6.64 (6.93) vs. 3.34 (3.99)) and SII (2505.86 (3957.47) × 10<sup>9</sup>/L vs. 1092.50 (1476.08) × 10<sup>9</sup><span>/L), and the levels of CRP (14.12 (12.66) mg/dL vs. 3.86 (12.63) mg/dL) and ESR (87.50 (50.50) mm/h vs. 63.00 (57.25) mm/h) were significantly higher in Group 1 than Group 2 (all p < 0.001). AUC of ROC analysis of PLR was 0.666 (95% CI, 0.604–0.728), NLR was 0.695 (95% CI, 0.638–0.752) and SII was 0.716 (95% CI, 0.661–0.772) for the predicting of amputation and the SII had the best AUC with 67.4% sensitivity and 63.3%specificty.</span></p></div><div><h3>Conclusion</h3><p>SII is a cost-effective and readily available marker, but alone may not be sufficient to predict the risk of amputation in DFU. In our results, the predictive role of SII alone or with other markers for future DFU and its role in predicting other chronic diabetic complications will be evaluated in extensive studies.</p></div>\",\"PeriodicalId\":16939,\"journal\":{\"name\":\"Journal of Orthopaedic Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Orthopaedic Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0949265823002038\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Orthopaedic Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0949265823002038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
摘要
目的:全身免疫炎症指数(SII)是通过淋巴细胞、中性粒细胞和血小板计数计算得出的一种具有成本效益的生物标志物,目前正在对各种疾病进行研究。由于目前还没有文献研究 SII 与糖尿病足溃疡(DFU)之间的关系,我们的目的是调查 SII 与糖尿病足溃疡截肢率之间的关系:从2017年至2021年筛查了2型DM 511名DFU患者。考虑了住院第一天获得的实验室数据。根据血常规计数计算血小板与淋巴细胞比值(PLR)、中性粒细胞与淋巴细胞比值(NLR)和SII。参与者分为截肢组(第 1 组)和未截肢组(第 2 组):结果:截肢率为 18.8%。A1c (8.80 (3.26) % vs. 9.52 (3.10) %, p = 0.007)、HGB (10.17 ± 2.16 g/dL vs. 12.05 ± 2.20 g/dL, p 9/L vs. 10.41 (5.82) × 109/L)、PLT (393.35 (196. 98) × 109/L vs. 31.41 (5.82) × 109/L)。98)×109/L vs. 312.05(141.33)×109/L)、中性粒细胞(11.52(8.75)×109/L vs. 6.93(5.96)×109/L)、PLR(226.04(159.24)×109/L vs. 153.12(101.91)×109/L)、NLR(6.64(6.93) vs. 3.34(3.99))和 SII(2505.86(3957.47)×109/L vs. 1092.50(1476.08)×109/L),以及 CRP 水平(14.12(12.66) mg/dL vs. 3.86 (12.63) mg/dL)和血沉(87.50 (50.50) mm/h vs. 63.00 (57.25) mm/h)明显高于第 2 组(均为 p 结论:SII 是一种经济有效的治疗方法:SII 是一种具有成本效益且容易获得的标记物,但仅靠它可能不足以预测 DFU 截肢的风险。根据我们的研究结果,SII 单独或与其他标记物一起对未来 DFU 的预测作用及其在预测其他慢性糖尿病并发症方面的作用将在广泛的研究中进行评估。
Relationship between systemic immune inflammation index and amputation in patients with diabetic foot ulcer
Aim
The systemic immune inflammation index (SII) is a cost-effective biomarker calculated by lymphocyte, neutrophil and platelet counts and is currently being studied in various diseases. Since there is no study examining the relationship between SII and diabetic foot ulcers (DFU) in the literature, our aim was to investigate the relationship between SII and amputation rate in DFU.
Methods
Type 2 DM 511 patients with DFU were screened from 2017 to 2021. Laboratory data obtained on the first day of hospitalization were considered. Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and SII were calculated from routine blood count. Participants were divided into two groups as amputation (Group 1) and non-amputation (Group 2).
Results
Amputation rate was 18.8%. The A1c (8.80 (3.26) % vs. 9.52 (3.10) %, p = 0.007) and HGB (10.17 ± 2.16 g/dL vs. 12.05 ± 2.20 g/dL, p < 0.001) levels, and lymphocyte count (1.81 (1.16) vs. 2.05 (1.11), p = 0.015) were significantly lower in Group 1 than Group 2. The counts of WBC (14.01 (9.16) × 109/L vs. 10.41 (5.82) × 109/L), PLT (393.35 (196.98) × 109/L vs. 312.05 (141.33) × 109/L), neutrophil (11.52 (8.75) × 109/L vs. 6.93 (5.96) × 109/L), PLR (226.04 (159.24) × 109/L vs. 153.12 (101.91) × 109/L), NLR (6.64 (6.93) vs. 3.34 (3.99)) and SII (2505.86 (3957.47) × 109/L vs. 1092.50 (1476.08) × 109/L), and the levels of CRP (14.12 (12.66) mg/dL vs. 3.86 (12.63) mg/dL) and ESR (87.50 (50.50) mm/h vs. 63.00 (57.25) mm/h) were significantly higher in Group 1 than Group 2 (all p < 0.001). AUC of ROC analysis of PLR was 0.666 (95% CI, 0.604–0.728), NLR was 0.695 (95% CI, 0.638–0.752) and SII was 0.716 (95% CI, 0.661–0.772) for the predicting of amputation and the SII had the best AUC with 67.4% sensitivity and 63.3%specificty.
Conclusion
SII is a cost-effective and readily available marker, but alone may not be sufficient to predict the risk of amputation in DFU. In our results, the predictive role of SII alone or with other markers for future DFU and its role in predicting other chronic diabetic complications will be evaluated in extensive studies.
期刊介绍:
The Journal of Orthopaedic Science is the official peer-reviewed journal of the Japanese Orthopaedic Association. The journal publishes the latest researches and topical debates in all fields of clinical and experimental orthopaedics, including musculoskeletal medicine, sports medicine, locomotive syndrome, trauma, paediatrics, oncology and biomaterials, as well as basic researches.